Treatment
Maribavir clinical trials
We’re tracking 7 recruiting studies that include Maribavir, each written for real people, not researchers, below.
Recruiting studies
- NCT06577363Recruiting
Maribavir tablets for CMV infection after transplant
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
Tokyo, TokyoAges Any age - NCT06439342RecruitingPhase 3
Maribavir for CMV in Chinese transplant recipients
This study tests a new medicine called maribavir for Chinese adults who have a CMV infection that hasn't gotten better with standard treatments. It may be an option for transplant recipients who need a different approach.
Hefei, AnhuiAges 18 years+ - NCT05319353RecruitingPhase 3
Maribavir for kids with CMV after transplant
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
Wilmington, DelawareAges Up to 17 years - NCT07014319RecruitingPhase 2
Maribavir for CMV in lymphoma patients on bispecific antibodies
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
SeoulAges 19 years+ - NCT07511127RecruitingPhase 3
Maribavir for stubborn CMV after stem cell transplant
This trial tests whether taking maribavir for different lengths of time can help treat a stubborn CMV infection after a stem cell transplant. It is for people whose CMV hasn't improved with standard treatment.
ShanghaiAges 18–75 - NCT06555432Recruiting
Study of maribavir for CMV infection after transplant
This study tests a medication called LIVTENCITY (maribavir) for adults in South Korea who have a CMV infection after a transplant. It is for people whose infection has not improved or has become resistant to other antiviral medicines.
SeoulAges 19 years+ - NCT06243731Recruiting
Maribavir for CMV after transplant in kidney failure
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
Anderlecht, Brussels CapitalAges 18 years+
What Maribavir is being studied for
Conditions with recruiting Maribavir studies.
Common questions
- Are there clinical trials studying Maribavir?
- Yes. Clin2 currently lists 7 recruiting studies that include Maribavir, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Maribavir trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Maribavir an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Maribavir or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.